-20°C, protect from light*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological activity
Description
Target:
In Vivo
NP-3 (oral administration; 150 μg DNA per mouse; single dose) at 12, 24, and 36 h postadministration, luciferin substrate is intraperitoneally injected to verify its permeability. NP-3 group maintains high luciferase expression in the liver, lung, and intestine areas 12-24 h post-treatment.Additionally, NP-3 exhibits 1.5 times higher signal intensity than that of NP-1 or NP-2 group from 12 to 24 h postoral administration[2].
In Vitro
NP-3 (0.05-1.6 mg/mL; 24 hours) does not decrease the cytotoxicity of cells in 293T, HepG2, A549, and HeLa cell lines, but the DPPC and DMG-PEG coated nanoparticles reduce cell cytotoxicity. In addition, the transfection efficiency of DPPC/DMG-PEG/(lPEI/DNA) nanoparticles (NP-3) in 293 cells is improved, and the maximum transfection efficiency (∼76% eGFP positive cells) is observed[1].
Kinase Assay
Cell Assay
Animal Administration
References
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
